Women with cystic fibrosis (CF) who had a lung transplant are at higher risk of testing positive for the…
Margarida Maia, PhD
Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Maia, PhD
The rate of new cases, or incidence of cystic fibrosis (CF) is gradually and annually decreasing in the U.S.
Most people with cystic fibrosis (CF) have fungi in their airways, but the fungi may come and go in…
Treatment with Trikafta continues to be safe and well-tolerated, benefiting people with cystic fibrosis (CF) ages 12 and…
A Phase 1b/2 clinical trial testing WRAIR-PAM-CF1, Adaptive Phage’s experimental cocktail of bacteriophages, or viruses that selectively target and…
Trikafta (elexacaftor/tezacaftor/ivacaftor) may bring health-related quality of life benefits to people with cystic fibrosis (CF) that go beyond those…
The bacteria that causes chronic rhinosinusitis — swelling of the nasal cavity and sinuses — in people with cystic…
Young patients with cystic fibrosis (CF) who have a lung infection caused by Staphylococcus bacteria may have worse lung…
A type of ring-shaped molecule called a macrocycle can help CFTR — the faulty protein in cystic fibrosis (CF)…
Kaftrio, a triple combination of elexacaftor, tezacaftor, and ivacaftor sold as Trikafta in the U.S., may ease acid reflux…